| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sara Samadzadeh, Rafl Adnan, Paulina Berglova, Mahdi Barzegar, Birgit Debrabant, Stine Gundtoft Roikjaer, Michael Levy, Axel Petzold, Jacqueline Palace, Eoin P Flanagan, Sara Mariotto, Soeren T Skou, Anne Froelich, Itay Lotan, Silvia Messina, Ruth Geraldes, Susanna Asseyer, Hadas Stiebel-Kalish, Frederike Cosima Oertel, Vahid Shaygannejad, Mohammad Ali Sahraian, Ho Jin Kim, Jeffrey L Bennett, Chotima Böttcher, Hanna G Zimmermann, Brian G Weinshenker, Friedemann Paul, Nasrin Asgar. Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT). Frontiers in immunology. vol 15. 2024-07-18. PMID:39021565. |
comorbidities in patients with multiple sclerosis (ms) and antibody-mediated diseases of the central nervous system (cns) including neuromyelitis optica spectrum disorder (nmosd), and myelin oligodendrocyte glycoprotein (mog)-antibody-associated disease (mogad) are common and may influence the course of their neurological disease. |
2024-07-18 |
2024-07-20 |
human |
| Carson E Moseley, Akash Virupakshaiah, Thomas G Forsthuber, Lawrence Steinman, Emmanuelle Waubant, Scott S Zamvi. MOG CNS Autoimmunity and MOGAD. Neurology(R) neuroimmunology & neuroinflammation. vol 11. issue 5. 2024-07-12. PMID:38996203. |
at one time considered a possible form of neuromyelitis optica (nmo) spectrum disorder (nmosd), it is now accepted that myelin oligodendrocyte glycoprotein (mog) antibody (ab)-associated disorder (mogad) is a distinct entity from either nmo or multiple sclerosis (ms) and represents a broad spectrum of clinical phenotypes. |
2024-07-12 |
2024-07-15 |
Not clear |
| Jodie M Burton, Saerom Youn, Abdullah Al-Ani, Fiona Costell. Correction to: Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid. Journal of neurology. 2024-07-05. PMID:38969877. |
correction to: patterns and utility of myelin oligodendrocyte glycoprotein (mog) antibody testing in cerebrospinal fluid. |
2024-07-05 |
2024-07-08 |
Not clear |
| María Dema, Herena Eixarch, Mireia Castillo, Xavier Montalban, Carmen Espej. IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis. International journal of molecular sciences. vol 25. issue 12. 2024-06-27. PMID:38928437. |
young and aged mice were immunized with myelin oligodendrocyte protein (mog) |
2024-06-27 |
2024-06-29 |
mouse |
| Y K Ananya, L Ramy. Deciphering the conformational dynamics of Myelin Oligodendrocyte glycoprotein in the myelin sheath. Journal of biomolecular structure & dynamics. 2024-06-24. PMID:38910432. |
myelin oligodendrocyte glycoprotein (mog) is a transmembrane protein in the myelin sheath. |
2024-06-24 |
2024-06-26 |
human |
| Anandu M Anto, Sai Vishnu Vardhan Allu, Samrachana Acharya, Trupti Vakde, Eghosa Omoregi, Udesh Pande. Uncovering the Diagnostic Challenge of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Case Study of Acute Bilateral Vision Loss. Cureus. vol 16. issue 5. 2024-06-21. PMID:38903369. |
despite a comprehensive workup and a temporal artery biopsy ruling out large vessel arteritis, the etiology of vision loss remained elusive until myelin oligodendrocyte glycoprotein (mog) antibody testing returned positive, implicating myelin oligodendrocyte glycoprotein antibody-associated disease (mogad). |
2024-06-21 |
2024-06-23 |
Not clear |
| Rocío Del Carmen Bravo-Miana, Jone Karmele Arizaga-Echebarria, David Otaegu. Central nervous system-derived extracellular vesicles: the next generation of neural circulating biomarkers? Translational neurodegeneration. vol 13. issue 1. 2024-06-20. PMID:38898538. |
in this sense, other surface biomarkers for cns-derived evs, such as glutamate aspartate transporter (glast) and myelin oligodendrocyte glycoprotein (mog), among others, have started to be used. |
2024-06-20 |
2024-06-22 |
Not clear |
| Maria Rodi, Anne-Lise de Lastic, Ioannis Panagoulias, Ioanna Aggeletopoulou, Kostas Kelaidonis, John Matsoukas, Vasso Apostolopoulos, Athanasia Mouzak. Myelin Oligodendrocyte Glycoprotein (MOG)35-55 Mannan Conjugate Induces Human T-Cell Tolerance and Can Be Used as a Personalized Therapy for Multiple Sclerosis. International journal of molecular sciences. vol 25. issue 11. 2024-06-19. PMID:38892275. |
myelin oligodendrocyte glycoprotein (mog)35-55 mannan conjugate induces human t-cell tolerance and can be used as a personalized therapy for multiple sclerosis. |
2024-06-19 |
2024-06-21 |
mouse |
| Hikari Kondo, Yuko Takeuchi, Junichi Niwa, Kenji Yoshida, Naoaki Takemura, Sachiko Hosoyama, Tomotsugu Kaga, Kimihiko Kaneko, Naoki Mabuch. Efficacy of steroid therapy in the acute stage of anti-NMDAR and anti-MOG antibody overlapping encephalitis: a case report and literature review. Frontiers in immunology. vol 15. 2024-06-19. PMID:38895128. |
recently, cases of overlapping encephalitis caused by anti-n-methyl-d-aspartate receptor (anti-nmdar) and anti-myelin oligodendrocyte glycoprotein (mog) antibodies have been reported, and their clinical characteristics are gradually becoming clear. |
2024-06-19 |
2024-06-21 |
Not clear |
| James A Varley, Dimitrios Champsas, Timothy Prossor, Giuseppe Pontillo, Omar Abdel-Mannan, Zhaleh Khaleeli, Axel Petzold, Ahmed T Toosy, Sachid A Trip, Heather Wilson, Dermot H Mallon, Cheryl Hemingway, Kshitij Mankad, Michael Kin Loon Chou, Andrew J Church, Melanie S Hart, Michael P Lunn, Wallace Brownlee, Yael Hacohen, Olga Ciccarell. Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children. Neurology. vol 103. issue 1. 2024-06-13. PMID:38870448. |
to test the performance of the 2023 myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) criteria in adults and children with inflammatory demyelinating conditions who were tested for mog antibodies (abs). |
2024-06-13 |
2024-06-16 |
Not clear |
| Simon V Arnett, Kerri Prain, Sudarshini Ramanathan, Sandeep Bhuta, Fabienne Brilot, Simon A Broadle. Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysis. Journal of neurology. 2024-06-11. PMID:38861035. |
one atypical case was associated with peripheral blood myelin oligodendrocyte glycoprotein (mog) antibodies, but subsequent clinical and radiological course was in keeping with ms. |
2024-06-11 |
2024-06-14 |
Not clear |
| Jose Carlos D Saballegue, Ma Luisa Gwenn P Tiongso. Rituximab Therapy for Double Seronegative Neuromyelitis Optica Spectrum Disease. Cureus. vol 16. issue 5. 2024-06-10. PMID:38854188. |
it may be aquaporin-4 seropositive, anti-myelin oligodendrocyte glycoprotein (mog) antibody seropositive, or double seronegative. |
2024-06-10 |
2024-06-14 |
Not clear |
| Giacomo Greco, Mario Risi, Stefano Masciocchi, Pietro Businaro, Eleonora Rigoni, Elisabetta Zardini, Silvia Scaranzin, Chiara Morandi, Luca Diamanti, Thomas Foiadelli, Maria Pia Giannoccaro, Luana Morelli, Rocco Liguori, Paolo Barone, Alessandra Tozzo, Alice Passarini, Stefano Gelibter, Francesco Patti, Paola Banfi, Anna Maria Simone, Alvino Bisecco, Martino Ruggieri, Davide Maimone, Giorgia Bruno, Sabrina Siliquini, Stefania Bova, Massimiliano Di Filippo, Roberta Lanzillo, Antonio Gallo, Elena Colombo, Diego Franciotta, Matteo Gastald. Clinical, prognostic and pathophysiological implications of MOG-IgG detection in the CSF: the importance of intrathecal MOG-IgG synthesis. Journal of neurology, neurosurgery, and psychiatry. 2024-06-06. PMID:38844341. |
cerebrospinal fluid myelin oligodendrocyte glycoprotein igg (csf mog-igg) are found in a proportion of patients with mog antibody-associated disorder (mogad) and have been associated with severe disease presentations. |
2024-06-06 |
2024-06-10 |
Not clear |
| Xin Wang, Yi Qu, Jiayu Fan, Huiqiang Re. Serum NfL and EGFR/NfL ratio mRNAs as biomarkers for phenotype and disease severity of myelin oligodendrocyte glycoprotein IgG-associated disease. Frontiers in immunology. vol 15. 2024-05-29. PMID:38807603. |
myelin oligodendrocyte glycoprotein (mog) igg is frequently elevated in pediatric patients with acquired demyelinating syndrome (ads). |
2024-05-29 |
2024-06-03 |
Not clear |
| S Sriram, Kwang Woon Kim, Åsa Ljunggren-Ros. Targeted DeSUMOylation as a therapeutic strategy for multiple sclerosis. Journal of neuroimmunology. vol 392. 2024-05-24. PMID:38788318. |
anacardic acid and tak981 inhibited activation of th17 cells and reduced clinical and pathological injury in il-17 mediated myelin oligodendrocyte glycoprotein (mog) induced eae. |
2024-05-24 |
2024-05-27 |
mouse |
| Mahesh Venkatachari, K S Ashwanth, Yugandhar Samireddypalle, Thirunavukkarasu Arun Bab. Moyamoya disease in a 5-year child secondary to MOG antibody-positive cerebral cortical encephalitis. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2024-05-24. PMID:38789689. |
evaluation of encephalitis revealed positivity for anti-myelin oligodendrocyte (mog) antibodies. |
2024-05-24 |
2024-05-27 |
Not clear |
| Niroshan Jeyakumar, Magdalena Lerch, Russell C Dale, Sudarshini Ramanatha. MOG antibody-associated optic neuritis. Eye (London, England). 2024-05-23. PMID:38783085. |
myelin oligodendrocyte glycoprotein (mog) antibody-associated disease (mogad) is a demyelinating disorder, distinct from multiple sclerosis (ms) and neuromyelitis optica spectrum disorder (nmosd). |
2024-05-23 |
2024-05-27 |
Not clear |
| Georgia A Wilke, Madeline Spencer, Carley A Gilman, Rejean Guerriero, Parker Bohm, Gregory P Van Stavern, Andrew R Le. Peripheral Retinal Haemorrhages in a Patient with MOG-Associated Optic Neuritis. Neuro-ophthalmology (Aeolus Press). vol 48. issue 3. 2024-05-18. PMID:38756341. |
ultimately, she was found to be positive for myelin oligodendrocyte glycoprotein (mog) antibodies, consistent with a diagnosis of mog-associated optic neuritis. |
2024-05-18 |
2024-05-27 |
Not clear |
| Ritu R Trivedi, Angela S Archambault, Clarice Pavlak, Matteo Gastaldi, Claudia Cantoni, Laura Ghezzi, Anne H Cross, Timothy M Miller, Gregory F W. Prevalence of anti-myelin oligodendrocyte glycoprotein antibodies across neuroinflammatory and neurodegenerative diseases. Journal of the neurological sciences. vol 461. 2024-05-14. PMID:38744216. |
inflammatory central nervous system (cns) diseases, such as multiple sclerosis (ms) and myelin oligodendrocyte glycoprotein (mog) antibody-associated disease (mogad), are characterized by humoral immune abnormalities. |
2024-05-14 |
2024-05-27 |
human |
| Yaping Zhang, Lei Tian, Jiang Chen, Xuan Liu, Kang Li, Huanliang Liu, Wenqing Lai, Yue Shi, Bencheng Lin, Zhuge X. Selective bioaccumulation of polystyrene nanoplastics in fetal rat brain and damage to myelin development. Ecotoxicology and environmental safety. vol 278. 2024-05-07. PMID:38714083. |
compared with control rats, ps-nps exposure caused a significant reduction in myelin basic protein (mbp) and myelin oligodendrocyte glycoprotein (mog) expression, a decrease in myelin thickness, an increase in cell apoptosis, and a decline in the oligodendrocyte population. |
2024-05-07 |
2024-05-27 |
rat |